Yu EY, et al. - Researchers performed a randomized phase 2 study of a heat shock protein 27 (Hsp27) targeting antisense, apatorsen with prednisone vs prednisone alone, in patients with metastatic castration resistant prostate cancer. Apatorsen + prednisone compared to prednisone alone seemed not influencing the proportion of castration resistant prostate cancer patients without disease progression at 12 weeks but was linked with marked PSA declines. Findings justify further evaluation of Hsp27 targeting in prostate cancer.